Keywords: ec, approves, b-ms/gilead, atripla, european, commission, approved
EC approves B-MS/Gilead's Atripla
Article | 24 December 2007
The European Commission has approved US drugmakers Bristol-Myers Squibb and Gilead Sciences' Atripla (efavirenz 600mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
